Skip to main content

Trikafta Dosage

Medically reviewed by Drugs.com. Last updated on Oct 11, 2021.

Generic name: Elexacaftor 100mg, Tezacaftor 50mg, Ivacaftor 75mg; Ivacaftor 150mg
Dosage form: kit

General Dosing Information

Swallow the tablets whole.

TRIKAFTA should be taken with fat-containing food. Examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, or meats [see Clinical Pharmacology (12.3)].

Recommended Dosage in Adults and Pediatric Patients Aged 6 Years and Older

Recommended dosage for adult and pediatric patients aged 6 years and older is provided in Table 1.

The morning and the evening dose should be taken approximately 12 hours apart. TRIKAFTA is for oral use.

Table 1: Recommended Dosage for Adult and Pediatric Patients aged 6 Years and Older
Age Morning Dose Evening Dose
6 to less than 12 years weighing less than 30 kgs Two tablets, each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg One tablet of ivacaftor 75 mg
6 to less than 12 years weighing 30 kgs or more Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg One tablet of ivacaftor 150 mg
12 years and older Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg One tablet of ivacaftor 150 mg

Information for Missed Doses:

If 6 hours or less have passed since the missed morning or evening dose, the patient should take the missed dose as soon as possible and continue on the original schedule.

If more than 6 hours have passed since:

  • the missed morning dose, the patient should take the missed dose as soon as possible and should not take the evening dose. The next scheduled morning dose should be taken at the usual time.
  • the missed evening dose, the patient should not take the missed dose. The next scheduled morning dose should be taken at the usual time.

Morning and evening doses should not be taken at the same time.

Recommended Dosage for Patients with Hepatic Impairment

No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh Class A) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. See Table 2. Liver function tests should be closely monitored [see Warnings and Precautions (5.1) and Adverse Reactions (6)].

Treatment is not recommended for patients with moderate hepatic impairment (Child-Pugh Class B). Use of TRIKAFTA in patients with moderate hepatic impairment should only be considered when there is a clear medical need, and the benefit exceeds the risk. If used, TRIKAFTA should be used with caution at a reduced dose (see Table 2) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Liver function tests should be closely monitored [see Warnings and Precautions (5.1) and Adverse Reactions (6)].

TRIKAFTA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), but the exposure is expected to be higher than in patients with moderate hepatic impairment. TRIKAFTA should not be used in patients with severe hepatic impairment [see Warnings and Precautions (5.1), Adverse Reactions (6), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Table 2: Recommended Dosage for use of TRIKAFTA in patients with hepatic impairment
Mild (Child-Pugh Class A) Moderate (Child-Pugh Class B) Severe (Child-Pugh Class C)
No dose adjustment Use of TRIKAFTA should only be considered when there is a clear medical need, and the benefit exceeds the risk.
If used, TRIKAFTA should be used with caution at a reduced dose, as follows:
  • Day 1: take two elexacaftor/tezacaftor/ivacaftor tablets in the morning
  • Day 2: take one elexacaftor/tezacaftor/ivacaftor tablet in the morning
  • Continue alternating Day 1 and Day 2 dosing thereafter.
  • No evening dose of ivacaftor tablet should be taken.
Should not be used

Dosage Adjustment for Patients Taking Drugs that are CYP3A Inhibitors

Table 3 describes the recommended dosage modification for TRIKAFTA when co-administered with strong (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin) or moderate (e.g., fluconazole, erythromycin) CYP3A inhibitors. Avoid food or drink containing grapefruit during TRIKAFTA treatment [see Warnings and Precautions (5.3), Drug Interactions (7.2) and Clinical Pharmacology (12.3)].

Table 3: Dosage Adjustment for Concomitant Use of TRIKAFTA with Moderate and Strong CYP3A Inhibitors
Moderate CYP3A Inhibitors
Day 1 Day 2 Day 3 Day 4*
*
Continue dosing with two elexacaftor/tezacaftor/ivacaftor tablets and one ivacaftor tablet on alternate days.
The evening dose of ivacaftor should not be taken.
Continue dosing with two elexacaftor/tezacaftor/ivacaftor tablets twice a week, approximately 3 to 4 days apart.
§
The evening dose of ivacaftor tablet should not be taken.
Morning Dose Two elexacaftor/tezacaftor/ivacaftor tablets One ivacaftor tablet Two elexacaftor/tezacaftor/ivacaftor tablets One ivacaftor tablet
Evening Dose No dose
Strong CYP3A Inhibitors
Day 1 Day 2 Day 3 Day 4
Morning Dose Two elexacaftor/tezacaftor/ivacaftor tablets No dose No dose Two elexacaftor/tezacaftor/ivacaftor tablets
Evening Dose§ No dose

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.